Literature DB >> 17872579

Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz.

O Kummer, E Mossdorf, M Battegay, L Elzi, M Bodmer, S Krähenbühl, M Haschke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17872579      PMCID： PMC2000242          DOI： 10.1136/gut.2007.126144

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  8 in total

1.  Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.

Authors:  Stephanie R Faucette; Tong-Cun Zhang; Rick Moore; Tatsuya Sueyoshi; Curtis J Omiecinski; Edward L LeCluyse; Masahiko Negishi; Hongbing Wang
Journal:  J Pharmacol Exp Ther       Date:  2006-10-13       Impact factor: 4.030

Review 2.  Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity.

Authors:  I M Arias; L M Gartner; M Cohen; J B Ezzer; A J Levi
Journal:  Am J Med       Date:  1969-09       Impact factor: 4.965

3.  Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Authors:  Margaret Johnson; Beatriz Grinsztejn; Claudia Rodriguez; Jeffrey Coco; Edwin DeJesus; Adriano Lazzarin; Kenneth Lichtenstein; Anna Rightmire; Serap Sankoh; Richard Wilber
Journal:  AIDS       Date:  2005-04-29       Impact factor: 4.177

4.  Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.

Authors:  Heidi R Kast; Bryan Goodwin; Paul T Tarr; Stacey A Jones; Andrew M Anisfeld; Catherine M Stoltz; Peter Tontonoz; Steve Kliewer; Timothy M Willson; Peter A Edwards
Journal:  J Biol Chem       Date:  2001-11-12       Impact factor: 5.157

5.  Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor.

Authors:  Wen Xie; Mei-Fei Yeuh; Anna Radominska-Pandya; Simrat P S Saini; Yoichi Negishi; Bobbie Sue Bottroff; Geraldine Y Cabrera; Robert H Tukey; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

6.  Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

Authors:  Robert L Murphy; Ian Sanne; Pedro Cahn; Praphan Phanuphak; Lisa Percival; Thomas Kelleher; Michael Giordano
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

7.  Effect of sodium phenobarbital on bilirubin metabolism in an infant with congenital, nonhemolytic, unconjugated hyperbilirubinemia, and kernicterus.

Authors:  J F Crigler; N I Gold
Journal:  J Clin Invest       Date:  1969-01       Impact factor: 14.808

8.  Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.

Authors:  Christopher Payan; Adeline Pivert; Patrice Morand; Samira Fafi-Kremer; Fabrice Carrat; Stanislas Pol; Patrice Cacoub; Christian Perronne; Françoise Lunel
Journal:  Gut       Date:  2007-03-15       Impact factor: 23.059
  8 in total
  2 in total

1.  Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up.

Authors:  Claudie Laprise; Jean-Guy Baril; Serge Dufresne; Helen Trottier
Journal:  AIDS Patient Care STDS       Date:  2013-07       Impact factor: 5.078

2.  Individualization of antiretroviral therapy.

Authors:  Rebecca Pavlos; Elizabeth J Phillips
Journal:  Pharmgenomics Pers Med       Date:  2011-12-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.